Advanced search
Publication Cover
Cutaneous and Ocular Toxicology Volume 27, 2008 - Issue 4
Submit an article Journal homepage
158
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Acute erythema and edematous skin reaction and ectropion following docetaxel in a patient with non-small cell lung cancer

Ali Osman Kaya Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
,
Suleyman Buyukberber Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, TurkeyCorrespondence[email protected]
,
Ugur Coskun Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
,
Ramazan Yildiz Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
,
Banu Ozturk Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
,
Emel Yaman Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
,
Esra Adisen Department Dermatology, Gazi University Faculty of Medicine, Ankara, Turkey
,
Mustafa Gureli Department of Pathology, Gazi University Faculty of Medicine, Ankara, Turkey
&
Mustafa Benekli Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
 show all
Pages 327-331 | Published online: 02 Dec 2008

References

  • MC Perry, CM Anderson, and RC Donehower. Chemotherapeutic agents. In: MD Abeloff, JO Armitage, JE Niederhuber, MB Kastan, and WG McKenna. Clinical Oncology. 3rd ed; Philadelphia, PA: Churchill Livingstone. 2004: 483–535.
  • J Gligorov, and JP Lotz. 2004. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9 (Suppl 2):3–8.
  • J Crown, M O'Leary, and WS Ooi. 2004. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9 (Suppl 2):24–32.
  • JR Rigas. 2004. Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 9 (Suppl 2):16–23.
  • GD Leonard, and JA Zujewski. 2003. Docetaxel-related skin, nail, and vascular toxicity. Ann Pharmacother 37:148.
  • D Eich, K Scharffetter-Kochanek, HT Eich, I Tantcheva-Poor, and T Krieg. 2002. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol 25:599–602.
  • DF Battafarano, GC Zimmerman, SA Older, JH Keeling, and HA Burris. 1995. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 76:110–115.
  • M Chen, AN Crowson, M Woofter, MB Luca, and CM Magro. 2004. Docetaxel (Taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 31:818–820.
  • O Correia, C Azevedo, E Pinto Ferreira, F Braga Cruz, and J Polonia. 1999. Nail changes secondary to docetaxel (Taxotere). Dermatology 198:288–290.
  • GC Zimmerman, JH Keeling, HA Burris, G Cook, R Irvin, J Kuhn, ML McCollough, and DD Von Hoff. 1995. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 131:202–206.
  • SP Dourakis, VA Sevastianos, A Alexopoulou, M Deutsch, and N Stavrianeas. 2002. Treatment side effects. Case 2. Toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy. J Clin Oncol 20:3030–3032.
  • C Moisidis, and V Mobus. 2005. Erythema multiforme major following docetaxel. Arch Gynecol Obstet 271:267–269.
  • http://www.fda.gov/MEDWATCH/index.html, February 2008.
  • M Tsalic, M Gilboa, B Visel, B Miller, and N Haim. 2006. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. Med Oncol 23:57–61.
  • CA Naranjo, U Busto, EM Sellers, P Sandor, I Ruiz, EA Roberts, E Janecek, C Domecq, and DJ Greenblatt. 1981. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245.
  • FK Engels, RA Mathot, and J Verweij. 2007. Alternative drug formulations of docetaxel: a review. Anticancer Drugs 18:95–103.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.